Business Wire

CA-C3.AI

Share
C3 AI Awarded Robust Omnibus U.S. Patent for End-to-End Enterprise AI Platform

C3 AI today announced that it was awarded a broad-ranging omnibus patent for the company’s end-to-end enterprise AI solution, C3 AI® Suite, further solidifying the company’s position as a leading enterprise AI software provider for accelerating digital transformation, as well as strengthening C3 AI’s intellectual property and competitive advantage.

The newly issued U.S. patent (No.10,817,530) was granted for “systems, methods, and devices for an enterprise AI application development platform.” The patent encompasses not only advanced data processing and AI application development, but also the extensive array of techniques necessary to build an end-to-end enterprise AI platform, including C3 AI’s unique model-driven architecture.

“This patent is the most significant and substantial we have been awarded to date,” said Thomas M. Siebel, CEO of C3 AI. "When we filed years ago, no one else conceived of a comprehensive, end-to-end solution with a model-driven architecture that accelerates the delivery and reduces the complexity of developing and operating enterprise AI applications. This sweeping patent further extends our leadership and maturity in this market as well as our commitment to protect our IP and our customers, ensuring their ability to rapidly deploy and scale AI with confidence to drive high-value outcomes across their business."

The comprehensive patent protects many methods and techniques that enable the development of enterprise AI applications, including:

  • Use of a model-driven architecture for the “design, development, deployment, and operation of next-generation cyber-physical software applications and business processes”
  • The “application of advanced data aggregation methods, data persistence methods, data analytics, and machine learning methods”
  • Methods for “implementing abstraction and continuous processing of the aggregated data using a model-driven architecture”
  • Embedding capabilities “in a model-driven architecture type system to recommend actions based on real-time analysis of petabyte-scale data sets and telemetry data from millions to billions of endpoints”
  • The use of an ontology, or canonical data mode, that “comprises conceptual domain models of various attributes and processes related to different entities or domains,” wherein “the various attributes and processes comprise persistence, data representations, data interrelationships, computing processes, or machine learning algorithms” and “is extensible to allow users of said application development platform to integrate new data formats”
  • A standardized data format that “comprises an aggregation and correlation of two or more data formats associated with the plurality of data stores, while ensuring automatic and guaranteed referential integrity of the underlying two or more data formats,” wherein “the standardized data format is automatically exposed and accessible through RESTful interfaces”
  • “A method comprising: storing time-series data in a key-value store and non-time-series data in a relational database; implementing, on an application development platform, abstraction over a plurality of data stores comprising the key-value store and the relational database, wherein the abstraction comprises a metadata-based mapping framework over a plurality of data formats associated with the plurality of data stores.”

“This appears to be a seminal patent,” said Bruce Sewell, a C3 AI director, and former general counsel of Apple and Intel. “A close reading reveals a number of fundamental concepts that appear both necessary and sufficient to deploy an enterprise AI application.”

C3 AI has invested over a decade building a leading platform that brings enterprise AI solutions across industries at global, industrial scale to drive digital transformation. The C3 AI Suite is a scalable, production-ready enterprise AI solution that enables organizations to rapidly design, develop, and deploy enterprise-scale AI applications on any public, private, or hybrid cloud environment. It allows organizations to integrate and unify massive, fragmented data sets from disparate enterprise and extraprise data stores and sensors, and apply machine learning algorithms to generate predictive insights that improve efficiency, reduce costs, increase revenue, enhance safety, and drive greater profitability.

At the core of the C3 AI Suite is an open, model-driven architecture that significantly simplifies and accelerates data science and the development of enterprise AI applications – from data integration and data management to model development, validation, and deployment. With C3 AI’s model-driven architecture, a small team of developers can build and deploy enterprise-class AI applications in a matter of weeks, with up to 99 percent less code compared to other methods, by using conceptual models of all the elements an application requires.

C3 AI is establishing a Technology Licensing Office to enable third parties to license C3 AI-patented technologies for use in their own products and solutions.

This new patent follows the issue of a patent awarded for advanced methods of data processing. C3 AI holds additional patents in the areas of cybersecurity, fraud detection, and energy data processing.

Patent details are available in the United States Trademark and Patent Office database .

About C3.ai, Inc.

C3.ai, Inc. (NYSE: AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EIG’s MidOcean Energy Completes Acquisition of Interest in Canada from PETRONAS17.12.2025 09:58:00 CET | Press release

MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the completion of its acquisition of a 20% interest in PETRONAS’ key entities in Canada. The transaction includes a 20% interest in the North Montney Upstream Joint Venture (“NMJV”), which holds PETRONAS’ upstream investment in Canada, and a 20% interest in the North Montney LNG Limited Partnership (“NMLLP”), which holds PETRONAS’ 25% participating interest in the LNG Canada Project. This strategic investment positions MidOcean across the LNG value chain, securing upstream resources and downstream liquefaction through the LNG Canada Project, with around 0.7 MTPA of associated LNG and potential to grow further. RBC Capital Markets acted as financial advisor to MidOcean, and Latham & Watkins acted as legal advisor. About EIG EIG is a leading institutional investor in the global energy and infrastru

Nexo Announces Landmark Crypto Partnership with Tennis Australia for Australian Open and Summer of Tennis17.12.2025 09:00:00 CET | Press release

Nexo has signed a landmark multi-year deal with Tennis Australia, covering the Australian Open and the Summer of Tennis. The partnership delivers exclusive experiences, including a feature in the Coachеs Pod. The announcement continues Nexo’s rapid global expansion, following three other major sports partnerships in 2025. Nexo, the premier digital assets platform, has entered a landmark multi-year global partnership with Tennis Australia, becoming the Official Crypto Partner of the Australian Open and the Summer of Tennis, including the United Cup, Adelaide International, Brisbane International, and Hobart International. This agreement marks the first time a digital asset company has partnered with a Grand Slam tournament, affirming Nexo’s prestige, long-term vision, and leadership at the intersection of elite sport and digital assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216497915/en/ Antoni Trenchev, Co-founde

Outpost24 Secures New Investment to Scale its Exposure Management and Identity Security Solutions17.12.2025 08:00:00 CET | Press release

The strategic funding from international investment firm Vitruvian Partners will advance the company’s platform, helping organizations rapidly transform threat data into decisive action and a more robust security posture. Outpost24, a leader in exposure management and identity security, today announced a new investment from Vitruvian Partners to fuel its next phase of global growth. This significant new funding will accelerate innovation across the company's platform, with a focus on integrating AI capabilities to optimize how security teams identify and neutralize critical vulnerabilities. The only European vendor recognized as an overall leader in the 2025 KuppingerCole Leadership Compass Report for Attack Surface Management, Outpost24 delivers a distinct approach to cyber defence that empowers security teams to gain a complete understanding of their digital and human risk landscape. Last week, Outpost24 announced the acquisition of Infinipoint, a specialist in device identity, postu

VeritasChain Unveils VAP Architecture, New Auditability Research, and Confirms Submissions to 58 Regulators Globally17.12.2025 08:00:00 CET | Press release

VeritasChain today unveiled its Verifiable AI Provenance Framework (VAP) architecture, published new research on verifiable audit trails, and confirmed informational submissions to 58 regulatory authorities across 43 jurisdictions. These milestones advance VeritasChain’s mission to establish a global framework for verifiable auditability in AI and algorithmic trading. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216433807/en/ Map indicates jurisdictions where regulatory outreach or informational submissions have been made as of Dec 2025. Verifiable AI Provenance Framework (VAP) VAP is a layered assurance architecture designed for independent verification of AI decision-making. It is not a single product, but a framework defining how cryptographic evidence and third-party verification interoperate across diverse systems. The architecture records decision-to-execution events as immutable audit trails, facilitating regulat

New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 07:00:00 CET | Press release

Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1 Significant improvements in itch were observed as early as 48 hours after initial treatment and steadily increased through to Day 141 Nemolizumab is the first approved monoclonal antibody that specifically targets and inhibits the signalling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in atopic dermatitis and prurigo nodularis2-4 Nemolizumab is approved by multiple regulatory authorities around the world for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, including in the U.S. and EU5,6 Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye